Transplant Benefit Score
This webapp allows the calculation of a number of tools used in liver transplantation. Click the menu button above for options.
The Transplant Benefit Score (TBS) is a national set of rules used in the UK to offer livers to named adult patients on the elective liver waiting list.
- Livers are offered nationally to named patient predicted to gain the most survival benefit from receiving the particular liver graft on offer.
- Utility - Need = Transplant benefit
- The benefit score is calculated by measuring the difference between the area under the waiting list survival curve and the area under the post-transplant survival curve over a 5-year interval.
- The information in this app is provided as an information resource only, and is not to be used alone for any diagnostic or treatment purpose.
Recipient
Recipient
Donor
Download
Reset values
Examples: recipient
Examples: donor
Examples: change over time
Selection criteria for adult elective transplantation
- Selection will be based primarily on risk of death without a transplant. Patients can be considered for elective transplantation if they have an anticipated length of life or survival in the absence of transplantation that is less than that obtained with a liver transplant.
- All patients selected for the elective adult liver transplant list must have a projected 5-year survival after transplantation of >50%. That figure may change in the future if/when donor numbers alter.
- Selection will be assessed secondarily on ability of transplantation to improve quality of life.
- All patients will need to be regularly reviewed to ensure that they continue to meet criteria and have not improved or become too sick to benefit from transplantation.
- When the clinical situation alters such that a patient no longer meets these criteria, the patient’s name must be removed from the national list.
Selection criteria for chronic liver disease
Patients can be selected if they fulfil one of the following criteria:
- Projected 1-year liver disease mortality without transplantation of >9%, predicted by a United Kingdom Model for End-Stage Liver Disease (UKELD) score of ≥49. The UKELD score is derived from the patient’s serum sodium, creatinine and bilirubin and International Normalised Ratio (INR) of the prothrombin time.
- Patients with porto-pulmonary hypertension (mean PAP >25 mmHg, <50 mmHg; PVR >120 dynes/s/cm-5; PCWP <15 mmHg) should have had a clinically significant response to one of long-acting prostacyclin (or analogues), sildenafil, or bosentan.
References
Code on Github
Bugs / feature requests
NHSBT Liver selection policy 18/07/2018
MELD
UKELD
MELD-Na
The information in this app is provided as an information resource for clinicians, and is not to be used for any diagnostic or treatment purposes.
Acute liver failure
ALD selection criteria
Category 1
- Aetiology: Paracetamol poisoning:
- pH <7.25 more than 24 hours after overdose and after fluid resuscitation.
Category 2
- Aetiology: Paracetamol poisoning: Co-existing:
- Prothrombin time >100 seconds or INR >6.5, AND
- Serum creatinine >300 μmol/l or anuria, AND
- Grade 3–4 encephalopathy
Category 3
- Aetiology: Paracetamol poisoning:
- Significant liver injury and coagulopathy following exclusion of other causes of hyperlactatemia (e.g. pancreatitis, intestinal ischemia) after adequate fluid resuscitation.
- Arterial lactate >5 mmol/l on admission, AND
- Arterial lactate >4 mmol/l 24 hours later, AND
- Presence of clinical hepatic encephalopathy.
Category 4
- Aetiology: Paracetamol poisoning: Two of the following three criteria (category 2) AND clinical evidence of deterioration (e.g. increased ICP, FiO2 >50%, increasing inotrope requirements) in the ABSENCE of clinical sepsis.
- Prothrombin time >100 seconds or INR >6.5, AND
- Serum creatinine >300 μmol/l or anuria, AND
- Grade 3–4 encephalopathy
References
Code on Github
Bugs / feature requests
NHSBT Liver selection policy 18/07/2018
MELD
UKELD
MELD-Na
The information in this app is provided as an information resource for clinicians, and is not to be used for any diagnostic or treatment purposes.
HCC
HCC selection criteria
Radiological assessment should include both MDCT and MRI with size being assessed by the widest dimensions on either scan. A tumour (for the purposes of counting numbers) will require to be identified as an arterialised focal abnormality with portal phase washout on MDCT or Gd enhanced MR. Other tumours are considered indeterminate and do not count.
Tumour rupture and an α-fetoprotein (AFP) >1,000 iu/ml are absolute contraindications to transplantation, as are extra-hepatic spread and macroscopic vascular invasion.
The following are criteria for transplantation listing:
- A single tumour ≤5cm diameter, OR
- Up to 5 tumours all ≤3cm, OR
- Single tumour >5cm and ≤7cm diameter where there has been no evidence of tumour progression, no extra-hepatic spread and no new nodule formation over a 6- month period. Locoregional therapy +/- chemotherapy may be given during that time. Their transplant list place may be considered from the time of their first staging scan.
Locoregional therapy should be considered for all transplant list patients who have a hepatocellular carcinoma.
It is recognised that different imaging modalities may identify differences both in number and size of tumour, but to qualify as an HCC will require a congruent lesion to be seen on a minimum of two different radiological modalities. There must be no radiological evidence of vascular invasion and no distant metastasis.
References
Code on Github
Bugs / feature requests
NHSBT Liver selection policy 18/07/2018
MELD
UKELD
MELD-Na
The information in this app is provided as an information resource for clinicians, and is not to be used for any diagnostic or treatment purposes.
Variant syndromes
Hepatopulmonary syndrome
Persistent and intractable pruritus
Recurrent cholangitis
Variant syndromes
Familial amyloidosis
Primary hyperlipidaemia
Polycystic liver disease
Hepatic epithelioid haemangioendothelioma
- Histological confirmation
- Two or more lesions not amenable to resection
- Local, low volume lymph node involvement does not necessarily preclude transplantation
- Minimum observation period of three months
Nodular regenerative hyperplasia
- Hereditary haemorrhagic telangiectasia
- Glycogen storage disease
- Primary hyperoxaluria
- Ornithine transcarbamylase deficiency
- Maple syrup urine disease
- Porphyria
- Amyloidosis – other
Variant syndrome in context of chronic liver disease
Diretic resistant ascites
Chronic hepatic encephalopathy
References
Code on Github
Bugs / feature requests
NHSBT Liver selection policy 18/07/2018
MELD
UKELD
MELD-Na
The information in this app is provided as an information resource for clinicians, and is not to be used for any diagnostic or treatment purposes.